Eli Lilly and Company

Operator of a biopharmaceutical company intended to discover and develop next-generation medicines for neurodegenerative diseases. The company is focused on developing small-molecule activators of glucocerebrosidase and advanced programs targeting the innate immune system that can accelerate the progression of several neurological diseases, enabling healthcare professionals to transform the lives of patients with treatments for various ailments.

Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, focused on developing cell-permeable macrocyclic peptide therapeutics. Founded in 2012 by Professors Matt Jacobson and Scott Lokey, the company utilizes proprietary computational design algorithms and innovative synthetic chemistry to create macrocycles targeting significant clinical challenges. Their approach involves an iterative design process that leverages large virtual libraries of diverse macrocycle scaffolds, selected for their permeability. Circle Pharma aims to address unmet clinical needs, particularly in the treatment of cancer, by focusing on intracellular protein-protein interactions through its novel macrocycle therapies, which can be delivered via multiple routes, including oral administration. The company's work is intended to enable healthcare professionals to advance internal development efforts in this critical area of medicine.

Strateos operates a robotic cloud laboratory that automates chemistry, biology, and tissue analysis to enhance drug discovery processes. By integrating advanced robotics, control systems, and sophisticated imaging and analytics software, Strateos allows pharmaceutical companies to discover new drug candidates more efficiently. The company emerged from a merger between Transcriptic, known for its pioneering robotic cloud laboratory platform, and 3Scan, which specialized in using automation and machine learning to analyze tissue samples. This combination enables Strateos to provide a comprehensive suite of technologies designed to streamline the drug discovery and early development phases. By transforming life science methodologies into data-driven processes, Strateos aims to create a more efficient and cost-effective approach to scientific research, positioning itself as a valuable partner to biotechnology firms seeking to innovate in the field.

Nido Biosciences, Inc., founded in 2018 and based in Boston, Massachusetts, operates in the healthcare services sector. The company specializes in biotechnology and personal health, aiming to innovate within these fields. Currently in stealth mode, Nido Biosciences is focused on developing solutions that address unmet needs in healthcare and personal health management.

AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. Founded in 2012 and headquartered in Vancouver, Canada, it has created a full-stack, AI-powered platform that analyzes natural immune systems to identify antibodies suitable for drug development. The company employs next-generation transgenic mice, which generate fully human antibodies, enhancing its ability to discover effective therapeutic candidates. AbCellera's innovative approach addresses the limitations of traditional antibody discovery by enabling faster and more precise identification of optimal clinical candidates. It has established partnerships with various pharmaceutical companies, including a significant collaboration with Eli Lilly and Company to explore multiple targets. Through its proprietary technologies and expertise, AbCellera aims to streamline the antibody discovery process and support the development of next-generation therapeutics.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc.; strategic partnership agreement with Illumina, Inc.; research collaboration agreement with Veracyte, Inc.; and strategic partnership agreement with Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Ltd. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut. Loxo Oncology, Inc. is a subsidiary of Eli Lilly and Company.

ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.

Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology.

Lodo Therapeutics Corporation is a drug discovery and development company dedicated to creating novel therapeutics derived from natural sources to address significant health challenges, particularly resistant infectious diseases and cancers. Founded to advance the scientific vision of Dr. Sean Brady from Rockefeller University, Lodo utilizes a genome-based, culture-independent platform to discover and characterize small molecules from microbial sources found in soil. By leveraging advancements in DNA sequencing and bioinformatics, the company aims to unlock the therapeutic potential of previously undiscovered molecules encoded in microbial DNA, with a focus on treating conditions that have high unmet medical needs. Lodo Therapeutics, supported by Accelerator Corporation, is headquartered in New York City, where its laboratory and offices are located within the Alexandria Center for Life Science.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, that specializes in the discovery, development, and commercialization of biotherapeutics, primarily for cancer treatment. The company’s leading candidates include ZW25, a bispecific antibody currently undergoing Phase I and II clinical trials targeting various cancers, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs advanced computational biotechnology techniques, utilizing proprietary molecular modeling and high-performance computing to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships and collaborations with several major pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Founded in 2003, Zymeworks continues to focus on developing innovative solutions for cancer and other serious diseases.

Lohmann is a manufacturer of feed additives and poultry vaccines, selling its products in over 80 countries around the world. Headquartered in Cuxhaven, Germany, Lohmann has a production facility there, a vaccine plant in Winslow, Maine, and is represented by 18 subsidiaries in Europe, Asia and North America. The focus of Lohmann is the development of vaccines and food components that help prevent diseases of animals used in food production.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, that specializes in the discovery, development, and commercialization of biotherapeutics, primarily for cancer treatment. The company’s leading candidates include ZW25, a bispecific antibody currently undergoing Phase I and II clinical trials targeting various cancers, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs advanced computational biotechnology techniques, utilizing proprietary molecular modeling and high-performance computing to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships and collaborations with several major pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Founded in 2003, Zymeworks continues to focus on developing innovative solutions for cancer and other serious diseases.

Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

ChemGen Corp., a privately held bioscience company.

ImClone Systems is a leader in the development and manufacture of therapeutic antibodies, focused on advancing oncology care through targeted biologic treatments for various cancers. Established in 1984, the company has cultivated a strong expertise in oncology and utilizes advancements in molecular biology, genomics, and antibody engineering to create a unique pipeline of product candidates aimed at specific genetic mechanisms involved in cancer progression. Besides its marketed product ERBITUX, ImClone is advancing several investigational monoclonal antibodies through various stages of clinical development, targeting major solid tumor types. Following its acquisition by Eli Lilly and Company in 2008, the company has enhanced its antibody pipeline by leveraging Lilly's global resources. ImClone's capabilities are further strengthened by its state-of-the-art, FDA-approved manufacturing facilities in Branchburg, New Jersey, which provide significant capacity for biologic production. The company's research headquarters are located in New York City, and it maintains international operations in Europe, emphasizing its commitment to addressing the medical needs of cancer patients worldwide.

As of August 20, 2008, SGX Pharmaceuticals, Inc. was acquired by Eli Lilly & Co. SGX Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of therapeutics for addressing unmet medical needs in oncology. The company's product pipeline includes drug candidates from its FAST drug discovery platform, which uses X-ray crystallography and complementary biophysical and biochemical methods, combined with medicinal and computational chemistry. Its drug development programs target the c-MET receptor tyrosine kinase (MET), an enzyme implicated in an array of cancers; and the BCR-ABL tyrosine kinase enzyme for the treatment of chronic myelogenous leukemia (CML), a bone marrow cancer. Under the MET development program, the company develops SGX523, which is in Phase I clinical development studies for solid tumor indications; and SGX126, a preclinical development product for solid tumors indications. Under the BCR-ABL Development Program, SGX Pharmaceuticals develops SGX393, an oral therapy for the second-line treatment of CML, which is in preclinical development studies. Its drug discovery technologies are also applied to a portfolio of oncology targets, including JAK2, a non-receptor tyrosine kinase involved in cytokine-induced signaling and growth regulation, survival, and differentiation of cells; RAS, a protein that regulates cell growth; and three other tyrosine kinases. The company has a license and collaboration agreement with Novartis Institutes for Biomedical Research, Inc., Cystic Fibrosis Foundation Therapeutics, Inc., National Institutes of Health, and Eli Lilly & Company. SGX Pharmaceuticals, formerly known as Structural GenomiX, Inc., was founded in 1998 and is headquartered in San Diego, California.

Serenex is a medical drug discovery and development company that focuses on oncology. The company develops Hsp90 product platform that provides a collection of small molecule Hsp90 inhibitors for cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases, such as Alzheimer's. It also develops SNX-1012, a product for oral mucositis in solid tumor patients. Serenex is a U.S.-based company that was founded in 2000 and it was acquired in 2008 by Pfizer.

Applied Molecular Evolution, Inc. discovers, optimizes, and develops human bio-therapeutics. Applied Molecular Evolution offers AMEsystem technology platform for the development of human biotherapeutic candidates.

Perlegen Sciences engages in the discovery and commercialization of genetic variations that provide physicians with information to improve the clinical decision-making process and patient treatment outcomes. Its products include MammaPLUS, a breast cancer risk stratifier and a panel of common genetic variants that stratifies individual genetic and background/clinical risk for those at moderately elevated risk for non-familial breast cancer, as well as impacts the risk for developing invasive breast cancer; and Genotype Browser Website that provides a way to access and view the results of a study of genetic variation in various diverse human populations. Perlegen Sciences, Inc. was founded in 2000 and is based in Mountain View, California.

Pacific Biotech develops and markets diagnostic tests for detection of pregnancy, infectious diseases, strep throat, and mononucleosis.